香港六合彩

香港六合彩 spinout Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has raised $225 million (拢173 million) through its initial public offering this month.

The funding success adds to an unprecedented summer that saw 香港六合彩 spinout companies raise 拢265 million of investment, which could transform patient outcomes. The Orchard Therapeutics IPO brought the total investment in 香港六合彩 gene therapy spinouts to 拢438 million so far this year.

Founded in 2015 through a partnership between 香港六合彩B and F Prime Capital Partners, Orchard Therapeutics is based on research by the groups of Professor Bobby Gaspar and Professor Adrian Thrasher at the 香港六合彩 Institute of Child Health. 香港六合彩B is the part of 香港六合彩 Innovation & Enterprise that specialises in commercialising technology.

Orchard Therapeutics' lead programme is for the treatment of a rare and fatal disorder called severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID), sometimes referred to as 鈥渂ubble baby鈥� syndrome in the press. Children with the disorder must be protected from any infections due to their highly fragile immune system.

Three other 香港六合彩 spinout companies working to deliver advanced therapeutics to treat a range of diseases benefitted from substantial investment this summer. They include Autolus Therapeutics Ltd, Athena Vision Ltd (acquired in the formation of MeiraGTx) and Freeline Ltd.

Links

Read more news from 香港六合彩 Innovation & Enterprise.听